Filing and business context
The supplied filing is a Form 10-Q for the quarter ended March 31, 2020. However, it identifies the registrant as AVRA Medical Robotics, Inc., not SS Innovations International, Inc. The filing describes an early-stage medical robotics developer focused on an AI-enabled autonomous system, initially for aesthetic skin-resurfacing procedures. The financial statements are unaudited.
Key financial metrics
| Metric | Q1 2020 / March 31, 2020 | Comparable period / December 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 in Q1 2019 |
| Operating expenses | $306,671 | $394,329 in Q1 2019 |
| Net loss | $307,015; $0.01 per share | $395,481; $0.02 per share in Q1 2019 |
| Operating cash flow | $(50,354) | $(107,686) in Q1 2019 |
| Cash and cash equivalents | $10,120 | $28,474 at December 31, 2019 |
| Total assets | $79,812 | $132,524 at December 31, 2019 |
| Current liabilities | $1,171,140 | $1,195,782 at December 31, 2019 |
| Stockholders’ deficit | $(1,091,328) | $(1,063,258) at December 31, 2019 |
Research and development expense was $2,000, versus $24,062 in Q1 2019; general and administrative expense was $304,671, versus $370,267. Interest expense was $344. No revenue or gross margin was reported. The filing reports no income tax provision. It does not provide a clear standalone debt total; current liabilities include $368,500 in related-party notes and $25,000 in promissory notes.
Cash declined by $18,354 during the quarter. Investing activities used $4,000, while financing activities provided $36,000. The company reported $100,000 of related-party notes and $20,000 of promissory notes converted into common stock as non-cash financing activity.
Material changes and management commentary
- Net loss narrowed by $88,466 year over year, alongside lower operating expenses, particularly R&D and G&A.
- Management said the company had no established revenue source sufficient to cover operating costs and relied on debt and equity financing and shareholder loans. It warned that additional funding was not committed and might not be available on acceptable terms; inability to raise funds could curtail R&D or require other strategic alternatives, and new financing could substantially dilute shareholders.
- The filing states that the stockholders’ deficit raises substantial doubt about the company’s ability to continue as a going concern.
- Management could not estimate COVID-19’s effects on 2020 operations, financial condition, or liquidity.
- The company described product development and regulatory plans, including an FDA process, but provided no quantified revenue, earnings, or financing guidance. These are forward-looking plans, not assurances of approval or commercialization.
Risks, contingencies, and unusual items
- Disclosure controls and procedures were reported ineffective as of March 31, 2020 due to material weaknesses referenced in the prior annual report. The filing says there were no material changes in internal control over financial reporting during the quarter.
- The filing describes a UCF research agreement extended through April 30, 2021 and a potential 1% royalty in any year sales of products using the relevant intellectual property exceed $20 million. It also reports that a $43,548 intellectual-property asset had been fully impaired.
- Subsequent-events disclosures include private offerings, borrowings, equity conversions, and share issuances in 2020 and 2021. These occurred after the reported quarter and should not be confused with Q1 2020 results.
- The filing reports no applicable legal proceedings and no material off-balance-sheet arrangements.
Most important facts to verify
- Confirm the intended issuer: the supplied metadata names SS Innovations International, Inc., but the filing identifies AVRA Medical Robotics, Inc.
- Verify the filing’s period, filing date, and subsequent-events chronology. The report is signed June 30, 2022 despite covering Q1 2020, and the text contains dates and descriptions that may be inconsistent.
- Review the original filed statements and notes for any transcription or presentation issues, including blank or unclear line items and inconsistencies in stockholders’ deficit figures.
- Assess AVRA’s near-term liquidity, related-party financing dependence, going-concern risk, and the dilution and terms associated with later financing.
- Verify the status of product development, FDA engagement, regulatory requirements, and any commercial revenue; the filing reports no revenue for the quarter.